Following initial successes in melanoma treatment, immunotherapy has rapidly become
established as a major treatment modality for multiple types of solid cancers, including a …

The success of immune checkpoint inhibitors (ICIs) in an increasing range of heavily
mutated tumor types such as melanoma has culminated in their exploration in different …

Despite the recent advances in the systemic treatment of metastatic colorectal cancer
(mCRC), prognostic outcomes have remained to be poor. Thus, what is needed is an …

Following initial success in melanoma and lung tumours, immune checkpoint inhibitors
(ICIs) are now well recognized as a major immunotherapy treatment modality for multiple …

Following dramatic success in many types of advanced solid tumors, interest in
immunotherapy for the treatment of colorectal cancer (CRC) is increasingly growing. Given …

Immunotherapy in colorectal cancer (CRC) has made great strides within the past decade.
Immune checkpoint inhibitors are a class of immunotherapy and have been shown to greatly …

The long-term remissions induced by immune-checkpoint inhibitors (ICIs) in many types of
cancers have opened up the possibility of a broader use of immunotherapy in less …

Colorectal cancer (CRC) remains a leading cause of cancer-related deaths in the United
States. Although immunotherapy has dramatically changed the landscape of treatment for …

The recent success of anti-PD1 drugs in metastatic colorectal cancer patients with mismatch
repair deficiency generated overwhelming enthusiasm for immunotherapy in the disease …

Despite lengthening survival, death rates from metastatic colorectal cancer (CRC) remain
unacceptably high, with a bright spot being the demonstration of durable responses in …